Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck Sharp & Dohme Corp.
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
MK-5172 in Combination with MK-8742 in Treatment-Naïve Subjects
•To evaluate the efficacy of MK-5172 in combination with MK-8742 as assessed by the proportion of subjects in the immediate treatment arm achieving SVR12 (Sustained Virologic Response 12 weeks after t...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX ? 23) and Prevnar 13? (Pneumococcal 13-Valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in Healthy Adults 50 Years of Age or Older Estudio multicéntrico y doble ciego de la seguridad, tolerabilidad e inmunogenicidad de una vacuna antineumocócica conjugada (V114) en comparación con una vacuna antineumocócica de polisacáridos (PNEUMOVAX?23) y Prevenar 13? (vacuna antineumocócica conjugada 13 valente [proteína diftérica CRM197]) en adultos sanos de 50 años o más de edad
1.-To demonstrate that the safety profile of a single dose of V114 is acceptable. 2.-To compare serotype-specific IgG geometric mean concentrations (GMCs), as measured by Merck?s pneumococcal elect...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Extension to the Odanacatib Fracture Trial (PN018)
(1) to assess long-term changes from baseline in total hip bone mineral density (BMD) after 10 years of treatment with odanacatib 50 mg once-weekly in postmenopausal osteoporotic women previously trea...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
MK-5172 in Combination with MK-8742 with and without Ribavirin (RBV) in HCV patients who failed Prior pegylated interferon (peg-IFN) and RBV treatment
1. To evaluate the efficacy of MK-5172 in combination with MK-8742 as assessed by the proportion of subjects achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy),...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Merck)
Update Il y a 4 ans
MK-0431A XR in Pediatric Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformain
In pediatric subjects with inadequate control on metformin therapy, after 20 weeks: 1. To asses)s the effect of the addition of sitagliptin (MK-0431A XR) compared with the addition of placebo on A1C ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
MK-5172/MK-8742 vs Sofosbuvir/PR in HCV GT1, 4 or 6 Infection
•To compare MK-5172A to SOF/PR in the treatment of HCV, as assessed by the proportion of subjects achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy), defined as...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co
Update Il y a 4 ans
MK-5172/MK-8742 in HCV G1, 4, 6 with Inherited Blood Disorders
•To evaluate the efficacy of MK-5172A as assessed by the proportion of subjects in the immediate treatment arm achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Japanese Children & Adolescents New Onset Fever & Neutropenia
To evaluate the safety and tolerability of caspofungin in Japanese pediatric patients.
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma (rrMM)
1. Compare the Progression Free Survival (PFS) as assessed by CAC blinded central review according to the International Myeloma Working Group response criteria, (IMWG criteria) between treatment arms....
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients with Homozygous Familial Hypercholesterolemia (HoFH)
In adults with HoFH on a stable dose of their regular medications, we wish to evaluate the effects of adding anacetrapib 100 mg for 12 weeks relative to placebo on plasma concentrations of bad cholest...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
2
3
4
5
6
7
8
9
10
11
Next